Bone destruction in multiple myeloma: pathogenesis and model as basis for therapeutic targeting of bone substance defects by etiology-based bone substitute material ((09) B01)

点击翻译按钮获取中文摘要

Aims of project B1 are 1) to increase understanding of progression of asymptomatic myeloma to symptomatic myeloma and further to relapsed myeloma which is linked to the development of myeloma bone disease as basis for further development of bone substitute materials. 2) Identification of patients who will benefit from a therapy using such materials. 3) In vitro testing of developed materials on myeloma cell lines and primary myeloma cells to direct the material development (particularly regarding the release of compounds, e.g. bortezomib, anti-BCMA/-Sclerostin antibodies, BMP-6) as well as functional validation using CRISPR/CAS9.